Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and Commercial [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
DURHAM, N.C., April 02, 2026 BUSINESS WIRE Target RWE , a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced key updates to its leadership team, including the promotion of Steve Swanson to chief commercial officer, alongside the appointments of Emily Akin as head of delivery and Ashley Pierce as head of finance. These leadership updates position the company to scale operations, accelerate growth, and further the delivery of our clinical evidence generation solutions, including real-world data and clinical trials. Now chief commercial officer, Swanson leads the company's commercial strategy, including business development, partnerships, and go-to-market execution. In this role, he is committed to building deeper, more strategic relationships with biopharma and healthcare partners to drive stronger collaboration and improve outcomes for clients, partners, and patients. In this new role, Akin oversees clinical and partnersh
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape [Yahoo! Finance]Yahoo! Finance
- Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma [TheStreet.com]TheStreet.com
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform [Yahoo! Finance]Yahoo! Finance
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories [Yahoo! Finance]Yahoo! Finance
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratoriesPR Newswire